Tag Archives: body

#437693 Video Friday: Drone Helps Explore ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

ICRES 2020 – September 28-29, 2020 – Taipei, Taiwan
AUVSI EXPONENTIAL 2020 – October 5-8, 2020 – [Online Conference]
IROS 2020 – October 25-29, 2020 – Las Vegas, Nev., USA
CYBATHLON 2020 – November 13-14, 2020 – [Online Event]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.

Clearpath Robotics and Boston Dynamics were obviously destined to partner up with Spot, because Spot 100 percent stole its color scheme from Clearpath, which has a monopoly on yellow and black robots. But seriously, the news here is that thanks to Clearpath, Spot now works seamlessly with ROS.

[ Clearpath Robotics ]

A new video created by Swisscom Ventures highlights a research expedition sponsored by Moncler to explore the deepest ice caves in the world using Flyability’s Elios drone. […] The expedition was sponsored by apparel company Moncler and took place over two weeks in 2018 on the Greenland ice sheet, the second largest body of ice in the world after Antarctica. Research focused on an area about 80 kilometers east of Kangerlussuaq, where scientists wanted to study the movement of water deep underground to better understand the effects of climate change on the melting ice.

[ Flyability ]

Shane Wighton of the “Stuff Made Here” YouTube channel, whose terrifying haircut machine we featured a few months ago, has improved on his robotic basketball hoop. It’s actually more than an improvement: It’s a complete redesign that nearly drove Wighton insane. But the result is pretty cool. It’s fun to watch him building a highly complicated system while always seeking simple and elegant designs for its components.

[ Stuff Made Here ]

SpaceX rockets are really just giant, explosion-powered drones that go into space sometimes. So let's watch more videos of them! This one is sped up, and puts a flight into just a couple of minutes.

[ SpaceX ]

Neato Robotics makes some solid autonomous vacuums, and these incremental upgrades feature improved battery life and better air filters.

[ Neato Robotics ]

A full-scale engineering model of NASA's Perseverance Mars rover now resides in a garage facing the Mars Yard at NASA's Jet Propulsion Laboratory in Southern California.

This vehicle system test bed rover (VSTB) is also known as OPTIMISM, which stands for Operational Perseverance Twin for Integration of Mechanisms and Instruments Sent to Mars. OPTIMISM was built in a warehouselike assembly room near the Mars Yard – an area that simulates the Red Planet's rocky surface. The rover helps the mission test hardware and software before it’s transmitted to the real rover on Mars. OPTIMISM will share the space with the Curiosity rover's twin MAGGIE.

[ JPL ]

Heavy asset industries like shipping, oil and gas, and manufacturing are grounded in repetitive tasks like locating items on large industrial sites — a tedious task that can take as long 45 minutes to find critical items like a forklift in an area that spans the size of multiple football fields. Not only is this work boring, it’s dangerous and inefficient. Robots like Spot, however, love this sort of work.

Spot can provide real-time updates on the location of assets and complete other mundane tasks. In this case, Spot is using software from Cognite to roam the vast shipyard to locate and manage more than 100,000 assets stored across the facility. What used to take humans hours can be managed on an ongoing basis by Spot — leaving employees to focus on more strategic tasks.

[ Cognite ]

The KNEXT Barista system helps high volume premium coffee providers who want to offer artisan coffee specialities in consistent quality.

[ Kuka ]

In this paper, we study this idea of generality in the locomotion domain. We develop a learning framework that can learn sophisticated locomotion behavior for a wide spectrum of legged robots, such as bipeds, tripeds, quadrupeds and hexapods, including wheeled variants. Our learning framework relies on a data-efficient, off-policy multi-task RL algorithm and a small set of reward functions that are semantically identical across robots.

[ DeepMind ]

Thanks Dave!

Even though it seems like the real risk of COVID is catching it from another person, robotics companies are doing what they can with UVC disinfecting systems.

[ BlueBotics ]

Aeditive develop robotic 3D printing solutions for the production of concrete components. At the heart of their production plant are two large robots that cooperate to manufacture the component. The automation technology they build on is a robotic shotcrete process. During this process, they apply concrete layer by layer and thus manufacture complete components. This means that their customers no longer dependent on formwork, which is expensive and time-consuming to create. Instead, their customers can manufacture components directly on a steel pallet without these moulds.

[ Aeditive ]

Something BIG is coming next month from Robotiq!

My guess: an elephant.

[ Robotiq ]

TurtleBot3 is a great little home robot, as long as you have a TurtleBot3-sized home.

[ Robotis ]

How do you calculate the coordinated movements of two robot arms so they can accurately guide a highly flexible tool? ETH researchers have integrated all aspects of the optimisation calculations into an algorithm. The hot-​wire cutter will be used, among other things, to develop building blocks for a mortar-​free structure.

[ ETH Zurich ]

And now, this.

[ RobotStart ] Continue reading

Posted in Human Robots

#437673 Can AI and Automation Deliver a COVID-19 ...

Illustration: Marysia Machulska

Within moments of meeting each other at a conference last year, Nathan Collins and Yann Gaston-Mathé began devising a plan to work together. Gaston-Mathé runs a startup that applies automated software to the design of new drug candidates. Collins leads a team that uses an automated chemistry platform to synthesize new drug candidates.

“There was an obvious synergy between their technology and ours,” recalls Gaston-Mathé, CEO and cofounder of Paris-based Iktos.

In late 2019, the pair launched a project to create a brand-new antiviral drug that would block a specific protein exploited by influenza viruses. Then the COVID-19 pandemic erupted across the world stage, and Gaston-Mathé and Collins learned that the viral culprit, SARS-CoV-2, relied on a protein that was 97 percent similar to their influenza protein. The partners pivoted.

Their companies are just two of hundreds of biotech firms eager to overhaul the drug-discovery process, often with the aid of artificial intelligence (AI) tools. The first set of antiviral drugs to treat COVID-19 will likely come from sifting through existing drugs. Remdesivir, for example, was originally developed to treat Ebola, and it has been shown to speed the recovery of hospitalized COVID-19 patients. But a drug made for one condition often has side effects and limited potency when applied to another. If researchers can produce an ­antiviral that specifically targets SARS-CoV-2, the drug would likely be safer and more effective than a repurposed drug.

There’s one big problem: Traditional drug discovery is far too slow to react to a pandemic. Designing a drug from scratch typically takes three to five years—and that’s before human clinical trials. “Our goal, with the combination of AI and automation, is to reduce that down to six months or less,” says Collins, who is chief strategy officer at SRI Biosciences, a division of the Silicon Valley research nonprofit SRI International. “We want to get this to be very, very fast.”

That sentiment is shared by small biotech firms and big pharmaceutical companies alike, many of which are now ramping up automated technologies backed by supercomputing power to predict, design, and test new antivirals—for this pandemic as well as the next—with unprecedented speed and scope.

“The entire industry is embracing these tools,” says Kara Carter, president of the International Society for Antiviral Research and executive vice president of infectious disease at Evotec, a drug-discovery company in Hamburg. “Not only do we need [new antivirals] to treat the SARS-CoV-2 infection in the population, which is probably here to stay, but we’ll also need them to treat future agents that arrive.”

There are currentlyabout 200 known viruses that infect humans. Although viruses represent less than 14 percent of all known human pathogens, they make up two-thirds of all new human pathogens discovered since 1980.

Antiviral drugs are fundamentally different from vaccines, which teach a person’s immune system to mount a defense against a viral invader, and antibody treatments, which enhance the body’s immune response. By contrast, anti­virals are chemical compounds that directly block a virus after a person has become infected. They do this by binding to specific proteins and preventing them from functioning, so that the virus cannot copy itself or enter or exit a cell.

The SARS-CoV-2 virus has an estimated 25 to 29 proteins, but not all of them are suitable drug targets. Researchers are investigating, among other targets, the virus’s exterior spike protein, which binds to a receptor on a human cell; two scissorlike enzymes, called proteases, that cut up long strings of viral proteins into functional pieces inside the cell; and a polymerase complex that makes the cell churn out copies of the virus’s genetic material, in the form of single-stranded RNA.

But it’s not enough for a drug candidate to simply attach to a target protein. Chemists also consider how tightly the compound binds to its target, whether it binds to other things as well, how quickly it metabolizes in the body, and so on. A drug candidate may have 10 to 20 such objectives. “Very often those objectives can appear to be anticorrelated or contradictory with each other,” says Gaston-Mathé.

Compared with antibiotics, antiviral drug discovery has proceeded at a snail’s pace. Scientists advanced from isolating the first antibacterial molecules in 1910 to developing an arsenal of powerful antibiotics by 1944. By contrast, it took until 1951 for researchers to be able to routinely grow large amounts of virus particles in cells in a dish, a breakthrough that earned the inventors a Nobel Prize in Medicine in 1954.

And the lag between the discovery of a virus and the creation of a treatment can be heartbreaking. According to the World Health Organization, 71 million people worldwide have chronic hepatitis C, a major cause of liver cancer. The virus that causes the infection was discovered in 1989, but effective antiviral drugs didn’t hit the market until 2014.

While many antibiotics work on a range of microbes, most antivirals are highly specific to a single virus—what those in the business call “one bug, one drug.” It takes a detailed understanding of a virus to develop an antiviral against it, says Che Colpitts, a virologist at Queen’s University, in Canada, who works on antivirals against RNA viruses. “When a new virus emerges, like SARS-CoV-2, we’re at a big disadvantage.”

Making drugs to stop viruses is hard for three main reasons. First, viruses are the Spartans of the pathogen world: They’re frugal, brutal, and expert at evading the human immune system. About 20 to 250 nanometers in diameter, viruses rely on just a few parts to operate, hijacking host cells to reproduce and often destroying those cells upon departure. They employ tricks to camouflage their presence from the host’s immune system, including preventing infected cells from sending out molecular distress beacons. “Viruses are really small, so they only have a few components, so there’s not that many drug targets available to start with,” says Colpitts.

Second, viruses replicate quickly, typically doubling in number in hours or days. This constant copying of their genetic material enables viruses to evolve quickly, producing mutations able to sidestep drug effects. The virus that causes AIDS soon develops resistance when exposed to a single drug. That’s why a cocktail of antiviral drugs is used to treat HIV infection.

Finally, unlike bacteria, which can exist independently outside human cells, viruses invade human cells to propagate, so any drug designed to eliminate a virus needs to spare the host cell. A drug that fails to distinguish between a virus and a cell can cause serious side effects. “Discriminating between the two is really quite difficult,” says Evotec’s Carter, who has worked in antiviral drug discovery for over three decades.

And then there’s the money barrier. Developing antivirals is rarely profitable. Health-policy researchers at the London School of Economics recently estimated that the average cost of developing a new drug is US $1 billion, and up to $2.8 billion for cancer and other specialty drugs. Because antivirals are usually taken for only short periods of time or during short outbreaks of disease, companies rarely recoup what they spent developing the drug, much less turn a profit, says Carter.

To change the status quo, drug discovery needs fresh approaches that leverage new technologies, rather than incremental improvements, says Christian Tidona, managing director of BioMed X, an independent research institute in Heidelberg, Germany. “We need breakthroughs.”

Putting Drug Development on Autopilot
Earlier this year, SRI Biosciences and Iktos began collaborating on a way to use artificial intelligence and automated chemistry to rapidly identify new drugs to target the COVID-19 virus. Within four months, they had designed and synthesized a first round of antiviral candidates. Here’s how they’re doing it.

1/5

STEP 1: Iktos’s AI platform uses deep-learning algorithms in an iterative process to come up with new molecular structures likely to bind to and disable a specific coronavirus protein. Illustrations: Chris Philpot

2/5

STEP 2: SRI Biosciences’s SynFini system is a three-part automated chemistry suite for producing new compounds. Starting with a target compound from Iktos, SynRoute uses machine learning to analyze and optimize routes for creating that compound, with results in about 10 seconds. It prioritizes routes based on cost, likelihood of success, and ease of implementation.

3/5

STEP 3: SynJet, an automated inkjet printer platform, tests the routes by printing out tiny quantities of chemical ingredients to see how they react. If the right compound is produced, the platform tests it.

4/5

STEP 4: AutoSyn, an automated tabletop chemical plant, synthesizes milligrams to grams of the desired compound for further testing. Computer-selected “maps” dictate paths through the plant’s modular components.

5/5

STEP 5: The most promising compounds are tested against live virus samples.

Previous
Next

Iktos’s AI platform was created by a medicinal chemist and an AI expert. To tackle SARS-CoV-2, the company used generative models—deep-learning algorithms that generate new data—to “imagine” molecular structures with a good chance of disabling a key coronavirus protein.

For a new drug target, the software proposes and evaluates roughly 1 million compounds, says Gaston-Mathé. It’s an iterative process: At each step, the system generates 100 virtual compounds, which are tested in silico with predictive models to see how closely they meet the objectives. The test results are then used to design the next batch of compounds. “It’s like we have a very, very fast chemist who is designing compounds, testing compounds, getting back the data, then designing another batch of compounds,” he says.

The computer isn’t as smart as a human chemist, Gaston-Mathé notes, but it’s much faster, so it can explore far more of what people in the field call “chemical space”—the set of all possible organic compounds. Unexplored chemical space is huge: Biochemists estimate that there are at least 1063 possible druglike molecules, and that 99.9 percent of all possible small molecules or compounds have never been synthesized.

Still, designing a chemical compound isn’t the hardest part of creating a new drug. After a drug candidate is designed, it must be synthesized, and the highly manual process for synthesizing a new chemical hasn’t changed much in 200 years. It can take days to plan a synthesis process and then months to years to optimize it for manufacture.

That’s why Gaston-Mathé was eager to send Iktos’s AI-generated designs to Collins’s team at SRI Biosciences. With $13.8 million from the Defense Advanced Research Projects Agency, SRI Biosciences spent the last four years automating the synthesis process. The company’s automated suite of three technologies, called SynFini, can produce new chemical compounds in just hours or days, says Collins.

First, machine-learning software devises possible routes for making a desired molecule. Next, an inkjet printer platform tests the routes by printing out and mixing tiny quantities of chemical ingredients to see how they react with one another; if the right compound is produced, the platform runs tests on it. Finally, a tabletop chemical plant synthesizes milligrams to grams of the desired compound.

Less than four months after Iktos and SRI Biosciences announced their collaboration, they had designed and synthesized a first round of antiviral candidates for SARS-CoV-2. Now they’re testing how well the compounds work on actual samples of the virus.

Out of 10
63 possible druglike molecules, 99.9 percent have never been synthesized.

Theirs isn’t the only collaborationapplying new tools to drug discovery. In late March, Alex Zhavoronkov, CEO of Hong Kong–based Insilico Medicine, came across a YouTube video showing three virtual-reality avatars positioning colorful, sticklike fragments in the side of a bulbous blue protein. The three researchers were using VR to explore how compounds might bind to a SARS-CoV-2 enzyme. Zhavoronkov contacted the startup that created the simulation—Nanome, in San Diego—and invited it to examine Insilico’s ­AI-generated molecules in virtual reality.

Insilico runs an AI platform that uses biological data to train deep-learning algorithms, then uses those algorithms to identify molecules with druglike features that will likely bind to a protein target. A four-day training sprint in late January yielded 100 molecules that appear to bind to an important SARS-CoV-2 protease. The company recently began synthesizing some of those molecules for laboratory testing.

Nanome’s VR software, meanwhile, allows researchers to import a molecular structure, then view and manipulate it on the scale of individual atoms. Like human chess players who use computer programs to explore potential moves, chemists can use VR to predict how to make molecules more druglike, says Nanome CEO Steve McCloskey. “The tighter the interface between the human and the computer, the more information goes both ways,” he says.

Zhavoronkov sent data about several of Insilico’s compounds to Nanome, which re-created them in VR. Nanome’s chemist demonstrated chemical tweaks to potentially improve each compound. “It was a very good experience,” says Zhavoronkov.

Meanwhile, in March, Takeda Pharmaceutical Co., of Japan, invited Schrödinger, a New York–based company that develops chemical-simulation software, to join an alliance working on antivirals. Schrödinger’s AI focuses on the physics of how proteins interact with small molecules and one another.

The software sifts through billions of molecules per week to predict a compound’s properties, and it optimizes for multiple desired properties simultaneously, says Karen Akinsanya, chief biomedical scientist and head of discovery R&D at Schrödinger. “There’s a huge sense of urgency here to come up with a potent molecule, but also to come up with molecules that are going to be well tolerated” by the body, she says. Drug developers are seeking compounds that can be broadly used and easily administered, such as an oral drug rather than an intravenous drug, she adds.

Schrödinger evaluated four protein targets and performed virtual screens for two of them, a computing-intensive process. In June, Google Cloud donated the equivalent of 16 million hours of Nvidia GPU time for the company’s calculations. Next, the alliance’s drug companies will synthesize and test the most promising compounds identified by the virtual screens.

Other companies, including Amazon Web Services, IBM, and Intel, as well as several U.S. national labs are also donating time and resources to the Covid-19 High Performance Computing Consortium. The consortium is supporting 87 projects, which now have access to 6.8 million CPU cores, 50,000 GPUs, and 600 petaflops of computational resources.

While advanced technologies could transform early drug discovery, any new drug candidate still has a long road after that. It must be tested in animals, manufactured in large batches for clinical trials, then tested in a series of trials that, for antivirals, lasts an average of seven years.

In May, the BioMed X Institute in Germany launched a five-year project to build a Rapid Antiviral Response Platform, which would speed drug discovery all the way through manufacturing for clinical trials. The €40 million ($47 million) project, backed by drug companies, will identify ­outside-the-box proposals from young scientists, then provide space and funding to develop their ideas.

“We’ll focus on technologies that allow us to go from identification of a new virus to 10,000 doses of a novel potential therapeutic ready for trials in less than six months,” says BioMed X’s Tidona, who leads the project.

While a vaccine will likely arrive long before a bespoke antiviral does, experts expect COVID-19 to be with us for a long time, so the effort to develop a direct-acting, potent antiviral continues. Plus, having new antivirals—and tools to rapidly create more—can only help us prepare for the next pandemic, whether it comes next month or in another 102 years.

“We’ve got to start thinking differently about how to be more responsive to these kinds of threats,” says Collins. “It’s pushing us out of our comfort zones.”

This article appears in the October 2020 print issue as “Automating Antivirals.” Continue reading

Posted in Human Robots

#437639 Boston Dynamics’ Spot Is Helping ...

In terms of places where you absolutely want a robot to go instead of you, what remains of the utterly destroyed Chernobyl Reactor 4 should be very near the top of your list. The reactor, which suffered a catastrophic meltdown in 1986, has been covered up in almost every way possible in an effort to keep its nuclear core contained. But eventually, that nuclear material is going to have to be dealt with somehow, and in order to do that, it’s important to understand which bits of it are just really bad, and which bits are the actual worst. And this is where Spot is stepping in to help.

The big open space that Spot is walking through is right next to what’s left of Reactor 4. Within six months of the disaster, Reactor 4 was covered in a sarcophagus made of concrete and steel to try and keep all the nasty nuclear fuel from leaking out more than it already had, and it still contains “30 tons of highly contaminated dust, 16 tons of uranium and plutonium, and 200 tons of radioactive lava.” Oof. Over the next 10 years, the sarcophagus slowly deteriorated, and despite the addition of that gigantic network of steel support beams that you can see in the video, in the late 1990s it was decided to erect an enormous building over the entire mess to try and stabilize it for as long as possible.

Reactor 4 is now snugly inside the massive New Safe Confinement (NSC) structure, and the idea is that eventually, the structure will allow for the safe disassembly of what’s left of the reactor, although nobody is quite sure how to do that. This is all just to say that the area inside of the containment structure offers a lot of good opportunities for robots to take over from humans.

This particular Spot is owned by the U.K. Atomic Energy Authority, and was packed off to Russia with the assistance of the Robotics and Artificial Intelligence in Nuclear (RAIN) initiative and the National Centre for Nuclear Robotics. Dr. Dave Megson-Smith, who is a researcher at the University of Bristol, in the U.K., and part of the Hot Robotics Facility at the National Nuclear User Facility, was one of the scientists lucky enough to accompany Spot on its adventure. Megson-Smith specializes in sensor development, and he equipped Spot with a collimated radiation sensor in addition to its mapping payload. “We actually built a map of the radiation coming out of the front wall of Chernobyl power plant as we were in there with it,” Megson-Smith told us, and was able to share this picture, which shows a map of gamma photon count rate:

Image: University of Bristol

Researchers equipped Spot with a collimated radiation sensor and use one of the data readings (gamma photon count rate) to create a map of the radiation coming out of the front wall of the Chernobyl power plant.

So what’s the reason you’d want to use a very expensive legged robot to wander around what looks like a very flat and robot friendly floor? As it turns out, the floor is very dusty in there, and a priority inside the NSC is to keep dust down as much as possible, since the dust is radioactive and gets on everything and is consequently the easiest way for radioactivity to escape the NSC. “You want to minimize picking up material, so we consider the total contact surface area,” says Megson-Smith. “If you use a legged system rather than a wheeled or tracked system, you have a much smaller footprint and you disturb the environment a lot less.” While it’s nice that Spot is nimble and can climb stairs and stuff, tracked vehicles can do that as well, so in this case, the primary driving factor of choosing a robot to work inside Chernobyl is minimizing those contact points.

Right now, routine weekly measurements in contaminated spaces at Chernobyl are done by humans, which puts those humans at risk. Spot, or a robot like it, could potentially take over from those humans, as a sort of “automated safety checker”

Right now, routine weekly measurements in contaminated spaces at Chernobyl are done by humans, which puts those humans at risk. Spot, or a robot like it, could potentially take over from those humans, as a sort of “automated safety checker” able to work in medium level contaminated environments.” As far as more dangerous areas go, there’s a lot of uncertainty about what Spot is actually capable of, according to Megson-Smith. “What you think the problems are, and what the industry thinks the problems are, are subtly different things.

We were thinking that we’d have to make robots incredibly radiation proof to go into these contaminated environments, but they said, “can you just give us a system that we can send into places where humans already can go, but where we just don’t want to send humans.” Making robots incredibly radiation proof is challenging, and without extensive testing and ruggedizing, failures can be frequent, as many robots discovered at Fukushima. Indeed, Megson-Smith that in Fukushima there’s a particular section that’s known as a “robot graveyard” where robots just go to die, and they’ve had to up their standards again and again to keep the robots from failing. “So the thing they’re worried about with Spot is, what is its tolerance? What components will fail, and what can we do to harden it?” he says. “We’re approaching Boston Dynamics at the moment to see if they’ll work with us to address some of those questions.

There’s been a small amount of testing of how robots fair under harsh radiation, Megson-Smith told us, including (relatively recently) a KUKA LBR800 arm, which “stopped operating after a large radiation dose of 164.55(±1.09) Gy to its end effector, and the component causing the failure was an optical encoder.” And in case you’re wondering how much radiation that is, a 1 to 2 Gy dose to the entire body gets you acute radiation sickness and possibly death, while 8 Gy is usually just straight-up death. The goal here is not to kill robots (I mean, it sort of is), but as Megson-Smith says, “if we can work out what the weak points are in a robotic system, can we address those, can we redesign those, or at least understand when they might start to fail?” Now all he has to do is convince Boston Dynamics to send them a Spot that they can zap until it keels over.

The goal for Spot in the short term is fully autonomous radiation mapping, which seems very possible. It’ll also get tested with a wider range of sensor packages, and (happily for the robot) this will all take place safely back at home in the U.K. As far as Chernobyl is concerned, robots will likely have a substantial role to play in the near future. “Ultimately, Chernobyl has to be taken apart and decommissioned. That’s the long-term plan for the facility. To do that, you first need to understand everything, which is where we come in with our sensor systems and robotic platforms,” Megson-Smith tells us. “Since there are entire swathes of the Chernobyl nuclear plant where people can’t go in, we’d need robots like Spot to do those environmental characterizations.” Continue reading

Posted in Human Robots

#437614 Video Friday: Poimo Is a Portable ...

Video Friday is your weekly selection of awesome robotics videos, collected by your Automaton bloggers. We’ll also be posting a weekly calendar of upcoming robotics events for the next few months; here's what we have so far (send us your events!):

IROS 2020 – October 25-29, 2020 – [Online]
ROS World 2020 – November 12, 2020 – [Online]
CYBATHLON 2020 – November 13-14, 2020 – [Online]
ICSR 2020 – November 14-16, 2020 – Golden, Colo., USA
Let us know if you have suggestions for next week, and enjoy today's videos.

Engineers at the University of California San Diego have built a squid-like robot that can swim untethered, propelling itself by generating jets of water. The robot carries its own power source inside its body. It can also carry a sensor, such as a camera, for underwater exploration.

[ UCSD ]

Thanks Ioana!

Shark Robotics, French and European leader in Unmanned Ground Vehicles, is announcing today a disinfection add-on for Boston Dynamics Spot robot, designed to fight the COVID-19 pandemic. The Spot robot with Shark’s purpose-built disinfection payload can decontaminate up to 2,000 m2 in 15 minutes, in any space that needs to be sanitized – such as hospitals, metro stations, offices, warehouses or facilities.

[ Shark Robotics ]

Here’s an update on the Poimo portable inflatable mobility project we wrote about a little while ago; while not strictly robotics, it seems like it holds some promise for rapidly developing different soft structures that robotics might find useful.

[ University of Tokyo ]

Thanks Ryuma!

Pretty cool that you can do useful force feedback teleop while video chatting through a “regular broadband Internet connection.” Although, what “regular” means to you is a bit subjective, right?

[ HEBI Robotics ]

Thanks Dave!

While NASA's Mars rover Perseverance travels through space toward the Red Planet, its nearly identical rover twin is hard at work on Earth. The vehicle system test bed (VSTB) rover named OPTIMISM is a full-scale engineering version of the Mars-bound rover. It is used to test hardware and software before the commands are sent up to the Perseverance rover.

[ NASA ]

Jacquard takes ordinary, familiar objects and enhances them with new digital abilities and experiences, while remaining true to their original purpose — like being your favorite jacket, backpack or a pair of shoes that you love to wear.

Our ambition is simple: to make life easier. By staying connected to your digital world, your things can do so much more. Skip a song by brushing your sleeve. Take a picture by tapping on a shoulder strap. Get reminded about the phone you left behind with a blink of light or a haptic buzz on your cuff.

[ Google ATAP ]

Should you attend the IROS 2020 workshop on “Planetary Exploration Robots: Challenges and Opportunities”? Of course you should!

[ Workshop ]

Kuka makes a lot of these videos where I can’t help but think that if they put as much effort into programming the robot as they did into producing the video, the result would be much more impressive.

[ Kuka ]

The Colorado School of Mines is one of the first customers to buy a Spot robot from Boston Dynamics to help with robotics research. Watch as scientists take Spot into the school's mine for the first time.

[ HCR ] via [ CNET ]

A very interesting soft(ish) actuator from Ayato Kanada at Kyushu University's Control Engineering Lab.

A flexible ultrasonic motor (FUSM), which generates linear motion as a novel soft actuator. This motor consists of a single metal cube stator with a hole and an elastic elongated coil spring inserted into the hole. When voltages are applied to piezoelectric plates on the stator, the coil spring moves back and forward as a linear slider. In the FUSM that uses the friction drive as the principle, the most important parameter for optimizing its output is the preload between the stator and slider. The coil spring has a slightly larger diameter than the stator hole and generates the preload by expanding in a radial direction. The coil springs act not only as a flexible slider but also as a resistive positional sensor. Changes in the resistance between the stator and the coil spring end are converted to a voltage and used for position detection.

[ Control Engineering Lab ]

Thanks Ayato!

We show how to use the limbs of a quadruped robot to identify fine-grained soil, representative for Martian regolith.

[ Paper ] via [ ANYmal Research ]

PR2 is serving breakfast and cleaning up afterwards. It’s slow, but all you have to do is eat and leave.

That poor PR2 is a little more naked than it's probably comfortable with.

[ EASE ]

NVIDIA researchers present a hierarchical framework that combines model-based control and reinforcement learning (RL) to synthesize robust controllers for a quadruped robot (the Unitree Laikago).

[ NVIDIA ]

What's interesting about this assembly task is that the robot is using its arm only for positioning, and doing the actual assembly with just fingers.

[ RC2L ]

In this electronics assembly application, Kawasaki's cobot duAro2 uses a tool changing station to tackle a multitude of tasks and assemble different CPU models.

Okay but can it apply thermal paste to a CPU in the right way? Personally, I find that impossible.

[ Kawasaki ]

You only need to watch this video long enough to appreciate the concept of putting a robot on a robot.

[ Impress ]

In this lecture, we’ll hear from the man behind one of the biggest robotics companies in the world, Boston Dynamics, whose robotic dog, Spot, has been used to encourage social distancing in Singapore and is now getting ready for FDA approval to be able to measure patients’ vital signs in hospitals.

[ Alan Turing Institute ]

Greg Kahn from UC Berkeley wrote in to share his recent dissertation talk on “Mobile Robot Learning.”

In order to create mobile robots that can autonomously navigate real-world environments, we need generalizable perception and control systems that can reason about the outcomes of navigational decisions. Learning-based methods, in which the robot learns to navigate by observing the outcomes of navigational decisions in the real world, offer considerable promise for obtaining these intelligent navigation systems. However, there are many challenges impeding mobile robots from autonomously learning to act in the real-world, in particular (1) sample-efficiency–how to learn using a limited amount of data? (2) supervision–how to tell the robot what to do? and (3) safety–how to ensure the robot and environment are not damaged or destroyed during learning? In this talk, I will present deep reinforcement learning methods for addressing these real world mobile robot learning challenges and show results which enable ground and aerial robots to navigate in complex indoor and outdoor environments.

[ UC Berkeley ]

Thanks Greg!

Leila Takayama from UC Santa Cruz (and previously Google X and Willow Garage) gives a talk entitled “Toward a more human-centered future of robotics.”

Robots are no longer only in outer space, in factory cages, or in our imaginations. We interact with robotic agents when withdrawing cash from bank ATMs, driving cars with adaptive cruise control, and tuning our smart home thermostats. In the moment of those interactions with robotic agents, we behave in ways that do not necessarily align with the rational belief that robots are just plain machines. Through a combination of controlled experiments and field studies, we use theories and concepts from the social sciences to explore ways that human and robotic agents come together, including how people interact with personal robots and how people interact through telepresence robots. Together, we will explore topics and raise questions about the psychology of human-robot interaction and how we could invent a future of a more human-centered robotics that we actually want to live in.

[ Leila Takayama ]

Roboticist and stand-up comedian Naomi Fitter from Oregon State University gives a talk on “Everything I Know about Telepresence.”

Telepresence robots hold promise to connect people by providing videoconferencing and navigation abilities in far-away environments. At the same time, the impacts of current commercial telepresence robots are not well understood, and circumstances of robot use including internet connection stability, odd personalizations, and interpersonal relationship between a robot operator and people co-located with the robot can overshadow the benefit of the robot itself. And although the idea of telepresence robots has been around for over two decades, available nonverbal expressive abilities through telepresence robots are limited, and suitable operator user interfaces for the robot (for example, controls that allow for the operator to hold a conversation and move the robot simultaneously) remain elusive. So where should we be using telepresence robots? Are there any pitfalls to watch out for? What do we know about potential robot expressivity and user interfaces? This talk will cover my attempts to address these questions and ways in which the robotics research community can build off of this work

[ Talking Robotics ] Continue reading

Posted in Human Robots

#437610 How Intel’s OpenBot Wants to Make ...

You could make a pretty persuasive argument that the smartphone represents the single fastest area of technological progress we’re going to experience for the foreseeable future. Every six months or so, there’s something with better sensors, more computing power, and faster connectivity. Many different areas of robotics are benefiting from this on a component level, but over at Intel Labs, they’re taking a more direct approach with a project called OpenBot that turns US $50 worth of hardware and your phone into a mobile robot that can support “advanced robotics workloads such as person following and real-time autonomous navigation in unstructured environments.”

This work aims to address two key challenges in robotics: accessibility and scalability. Smartphones are ubiquitous and are becoming more powerful by the year. We have developed a combination of hardware and software that turns smartphones into robots. The resulting robots are inexpensive but capable. Our experiments have shown that a $50 robot body powered by a smartphone is capable of person following and real-time autonomous navigation. We hope that the presented work will open new opportunities for education and large-scale learning via thousands of low-cost robots deployed around the world.

Smartphones point to many possibilities for robotics that we have not yet exploited. For example, smartphones also provide a microphone, speaker, and screen, which are not commonly found on existing navigation robots. These may enable research and applications at the confluence of human-robot interaction and natural language processing. We also expect the basic ideas presented in this work to extend to other forms of robot embodiment, such as manipulators, aerial vehicles, and watercraft.

One of the interesting things about this idea is how not-new it is. The highest profile phone robot was likely the $150 Romo, from Romotive, which raised a not-insignificant amount of money on Kickstarter in 2012 and 2013 for a little mobile chassis that accepted one of three different iPhone models and could be controlled via another device or operated somewhat autonomously. It featured “computer vision, autonomous navigation, and facial recognition” capabilities, but was really designed to be a toy. Lack of compatibility hampered Romo a bit, and there wasn’t a lot that it could actually do once the novelty wore off.

As impressive as smartphone hardware was in a robotics context (even back in 2013), we’re obviously way, way beyond that now, and OpenBot figures that smartphones now have enough clout and connectivity that turning them into mobile robots is a good idea. You know, again. We asked Intel Labs’ Matthias Muller why now was the right time to launch OpenBot, and he mentioned things like the existence of a large maker community with broad access to 3D printing as well as open source software that makes broader development easier.

And of course, there’s the smartphone hardware: “Smartphones have become extremely powerful and feature dedicated AI processors in addition to CPUs and GPUs,” says Mueller. “Almost everyone owns a very capable smartphone now. There has been a big boost in sensor performance, especially in cameras, and a lot of the recent developments for VR applications are well aligned with robotic requirements for state estimation.” OpenBot has been tested with 10 recent Android phones, and since camera placement tends to be similar and USB-C is becoming the charging and communications standard, compatibility is less of an issue nowadays.

Image: OpenBot

Intel researchers created this table comparing OpenBot to other wheeled robot platforms, including Amazon’s DeepRacer, MIT’s Duckiebot, iRobot’s Create-2, and Thymio. The top group includes robots based on RC trucks; the bottom group includes navigation robots for deployment at scale and in education. Note that the cost of the smartphone needed for OpenBot is not included in this comparison.

If you’d like an OpenBot of your own, you don’t need to know all that much about robotics hardware or software. For the hardware, you probably need some basic mechanical and electronics experience—think Arduino project level. The software is a little more complicated; there’s a pretty good walkthrough to get some relatively sophisticated behaviors (like autonomous person following) up and running, but things rapidly degenerate into a command line interface that could be intimidating for new users. We did ask about why OpenBot isn’t ROS-based to leverage the robustness and reach of that community, and Muller said that ROS “adds unnecessary overhead,” although “if someone insists on using ROS with OpenBot, it should not be very difficult.”

Without building OpenBot to explicitly be part of an existing ecosystem, the challenge going forward is to make sure that the project is consistently supported, lest it wither and die like so many similar robotics projects have before it. “We are committed to the OpenBot project and will do our best to maintain it,” Mueller assures us. “We have a good track record. Other projects from our group (e.g. CARLA, Open3D, etc.) have also been maintained for several years now.” The inherently open source nature of the project certainly helps, although it can be tricky to rely too much on community contributions, especially when something like this is first starting out.

The OpenBot folks at Intel, we’re told, are already working on a “bigger, faster and more powerful robot body that will be suitable for mass production,” which would certainly help entice more people into giving this thing a go. They’ll also be focusing on documentation, which is probably the most important but least exciting part about building a low-cost community focused platform like this. And as soon as they’ve put together a way for us actual novices to turn our phones into robots that can do cool stuff for cheap, we’ll definitely let you know. Continue reading

Posted in Human Robots